BIOCEPT INC: management transactions · United States · SEC (Form 4)

About BIOCEPT INC

Biocept Inc. is a U.S.-based molecular oncology diagnostics company that built its business around liquid biopsy technologies. Founded in California in May 1997, the company developed proprietary assays designed to detect circulating tumor cells and circulating tumor DNA from standard blood samples, as well as specialized tests using cerebrospinal fluid. Its clinical intent was to help physicians identify actionable cancer-related alterations at diagnosis, during progression, or when monitoring for resistance mechanisms. Biocept also commercialized CNSide, a cerebrospinal-fluid-based platform aimed at detecting tumor cells in patients with cancers that have spread to the central nervous system. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1044378/000095017023042468/R20.htm?utm_source=openai)) From a market standpoint, Biocept was listed on NASDAQ under the ticker BIOC, placing it within the U.S. public equity universe that is typically followed by investors looking for high-risk, high-upside biotech and diagnostics names. However, the company’s investment case has changed materially. Recent SEC-related evidence and third-party filings show that Biocept entered a distressed situation in which substantial assets were sold through a bankruptcy process, making the current story much more about asset realization than about a normal operating diagnostics franchise. ([businesswire.com](https://www.businesswire.com/news/home/20230524005953/en/Biocept-Announces-Pricing-of-%245.0-Million-Underwritten-Public-Offering?utm_source=openai)) Operationally, Biocept’s historical business lines were concentrated in oncology laboratory testing, liquid-biopsy assay development, and clinical diagnostic services. Its key offering set included proprietary blood-based biomarker tests, CNSide-based testing in cerebrospinal fluid, and related laboratory services targeted at oncologists, hospitals, and specialty cancer centers. The company’s competitive position was always nuanced: liquid biopsy is an attractive area because it can reduce reliance on invasive tissue sampling, but it is also intensely competitive and scientifically demanding. Biocept operated in a field populated by larger, better-capitalized diagnostics companies with broader commercialization capabilities and deeper reimbursement infrastructure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1044378/000095017023042468/R20.htm?utm_source=openai)) Geographically, Biocept’s core operations were centered in the United States, and the company historically served primarily the domestic oncology diagnostics market. Its headquarters and laboratory/manufacturing footprint were in San Diego, California, in earlier SEC filings, reflecting its West Coast life-science base. More recently, the key strategic event was the 2024 sale of substantially all rights to the CNSide platform after approval by the U.S. Bankruptcy Court for the District of Delaware. That transaction is the most material recent development for investors, because it indicates that the company’s economic value has been largely transferred out of the listed shell and into asset sale proceeds. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1044378/000156459022013599/bioc-10k_20211231.htm?utm_source=openai))